Marieke van Son

136 CHAPTER 7 REFERENCES 1. Magee DE, Singal RK. Androgen depri- vation therapy: indications, methods of utilization, side effects and their man- agement. The Canadian journal of urol- ogy. 2020;27(1S1):11-6. 2. Muniyan S, Xi L, Datta K, Das A, Teply BA, Batra SK, et al. Cardiovascular risks and toxicity - The Achilles heel of an- drogen deprivation therapy in prostate cancer patients. Biochim Biophys Acta Rev Cancer. 2020:188383. 3. Crook JM, Zhang P, Pisansky TM, Tra- bulsi EJ, Amin MB, Bice W, et al. A Pro- spective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). Int J Radiat Oncol Biol Phys. 2019;103(2):335-43. 4. Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, et al. Impact of (68) Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospec- tive Single-Arm Clinical Trial. Journal of nuclear medicine : official publica- tion, Society of Nuclear Medicine. 2020. 5. Duijzentkunst DA, Peters M, van der Voort van Zyp JR, Moerland MA, van Vulpen M. Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehen- sive review. World journal of urology. 2016;34(11):1521-31. 6. van Son M, Peters M, Moerland M, Kerk- meijer L, Lagendijk J, van der Voort van Zyp J. Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives. Cancers. 2018;10(12). 7. Haj-Hamed M, Karivedu V, Sidana A. Salvage treatment for radio-recurrent prostate cancer: a review of literature with focus on recent advancements in image-guided focal salvage therapies. International urology and nephrology. 2019;51(7):1101-6. 8. van Son MJ, Peters M, Moerland MA, La- gendijk JJW, Eppinga WSC, Shah TT, et al. MRI-guided ultrafocal salvage high- dose-rate brachytherapy for localized radiorecurrent prostate cancer: updated results of 50 patients. Int J Radiat Oncol Biol Phys. 2020. 9. van Son M, Monninkhof E, Peters M, Lagendijk J, van der Voort van Zyp J. Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent pros- tate cancer: reporting the patient’s perspective. Clinical and translational radiation oncology. 2020;25:81-7. 10. Maenhout M, Peters M, van Vulpen M, Moerland MA, Meijer RP, van den Bosch M, et al. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Pa- tients With Radiorecurrent Prostate Cancer. Technology in cancer research & treatment. 2017;16(6):1194-201. 11. Bates D, Machler M, Bolker BM, Walker SC. Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw. 2015;67(1):1-48. 12. National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [Available from: https:// ctep.cancer.gov/protocoldevelopment/ electronic_applications/ctc.htm. 13. Jiang P, van der Horst C, Kimmig B, Zins- ser F, Poppe B, Luetzen U, et al. Inter- stitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome. Brachytherapy. 2017;16(1):186-92. 14. Murgic J, Morton G, Loblaw A, D’Ali- monte L, Ravi A, Wronski M, et al. Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Fail- ure: Results From a Prospective Clini- cal Trial. Int J Radiat Oncol Biol Phys. 2018;102(3):561-7.